Teplizumab is a type of immunotherapy that works by tackling the root cause of diabetes. The drug tells the immune system not to attack pancreatic cells which produce insulin.
Provention Bio (PRVB.O) said on Thursday the US Food and Drug Administration had approved the use of its drug teplizumab in those aged eight years and older, the first treatment aimed at delaying the onset of insulin-dependent type 1 diabetes.
/PRNewswire/ Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated.
/PRNewswire/ Sanofi US has announced it has entered into a co-promotion service agreement with Provention Bio, Inc., for the commercialization of teplizumab.
Provention Bio, Inc. (NASDAQ:NASDAQ:PRVB) Q2 2022 Earnings Conference Call August 4, 2022 8:00 AM ET Company Participants Robert Doody - Vice President, Investor Relations Thierry Chauche -.